Poor outcomes associated with low lipid and lipoprotein levels

Critical Care Medicine

Volumn 32, Issue 3, 2004, Pages 878-879

  Gordon, Bruce R ^a  

^a ROGOSIN INSTITUTE   (United States)

Author keywords

Apolipoprotein A l, lipoprotein; Cytokines; High density lipoprotein; Inflammation; Intensive care; Total cholesterol

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CANCER; CHOLESTEROL BLOOD LEVEL; CRITICAL ILLNESS; DATA ANALYSIS; DISEASE EXACERBATION; EDITORIAL; HUMAN; INFECTION; INTENSIVE CARE; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; HUMANS; INTENSIVE CARE UNITS; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 1542614266     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000117318.84442.9F     Document Type: Editorial

References (21)

1. Thannhauser SJ, Schaber H: Uber die beziehungen des gleichgewichtes cholesterin und ctiolesterinester im blut und serum zur leberfunkton. Klinische Wochenschrift 1926; 7:252-253
2. Alvarez C, Ramos A: Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986; 32:142-145
3. Budd D, Ginsberg H: Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 1986; 58:1361-1365
4. Gordon BR, Parker TS, Levine DM, et al: Low lipid levels in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med 1996; 24:584-589
5. Levels JH, Lemaire LC, van den Ende AE, et al: Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003; 31: 1647-1653
6. Jacobs D, Blackburn H, Higgins M, et al: Report of the conference on low blood cholesterol: Mortality associations. Circulation 1992; 86:1046-1060
7. Schatz IJ, Masaki K, Yano K, et al: Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001; 358:351-355
8. Iribarren C, Jacobs DR Jr, Sidney S, et al: Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998; 121:335-347
9. Gordon BR, Parker TS, Levine DM, et al: Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001; 29: 1563-1568
10. Vanni HE, Gordon BR, Levine DM, et al: Cholesterol and interkeukin-6 concentrations relate to outcomes in burn-injured patients. J Burn Care Rehabil 2003; 24: 133-141
11. Chenaud C, Merlani PG, Roux-Lombard P, et al: Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004; 32:632-637
12. Ettinger WH, Varma VK, Sorci-Thomas M, et al: Cytokines decrease apolipoprotein accumulation in medium from HEP G2 cells. Arterioscler Thromb 1994; 14:8-13
13. Spriggs DR, Sherman ML, Michie H: Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039-1044
14. van Gameren MM, Willemse PH, Mulder NH, et al: Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood 1994; 84:1434-441
15. Hyka N, Dayer JM, Modoux C, et al: Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97:2381-2389
16. Ulevitch RJ, Johnston AR, Weinstein DB: New function for high density lipoproteins: Isolation and characterization of a bacterial lipopolysaccharide- high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67:827-837
17. Hubsch AP, Powell FS, Lerch PG, et al: A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23
18. Pajkrt D, Doran JE, Koster F, et al: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-1608
19. Kitchens RL, Thompson PA, Munford RS, et al: Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003; 44:2339-2348
20. Nissen SE, Tsunoda T, Tuzcu EM, et al: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290:2292-2300
21. Gordon BR, Parker TS, Levine DM, et al: Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion. Ann Pharmacother 2003; 37:943-950